TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11127933

Group type: EXPERIMENTAL
Intervention: Anticytokine antibodies, cytokines or cytokine-modifying agents
Number of subjects: 0
Study: 8803588

Group type: EXPERIMENTAL
Intervention: Captopril 6.25 mg orally (first dose) 2-4 hours after starting thrombolysis, increased up to 25 mg every 8 hours.
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo after thrombolysis.
Number of subjects: 45
Study: 1379009

Group type: EXPERIMENTAL
Intervention: 10% HAES 130/0.5
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 10% HAES 200/0.5
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (no volume therapy)
Number of subjects: 45
Study: 31444839

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 129
Study: 29764902

Group type: EXPERIMENTAL
Intervention: Community engagement intervention facilitated by laywomen for 3 years
Number of subjects: 30187

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30187
Study: 27706526

Group type: EXPERIMENTAL
Intervention: Self-learning software
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (procedure video)
Number of subjects: 39
Study: 24446955

Group type: EXPERIMENTAL
Intervention: Group psychoeducation sessions (3 successive monthly sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine seizure clinic follow-up visits
Number of subjects: 0
Study: 22721576

Group type: EXPERIMENTAL
Intervention: TAVI
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: AVR
Number of subjects: 900

Group type: COMPARATOR
Intervention: Medical and balloon aortic valvuloplasty
Number of subjects: 900
Study: 20515982

Group type: EXPERIMENTAL
Intervention: Minimized extracorporeal circulation (MECC)
Number of subjects: 99
Study: 19035244

Group type: EXPERIMENTAL
Intervention: Bimanual microincision cataract surgery (MICS)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Small incision cataract surgery (SICS)
Number of subjects: 280
Study: 16801644

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication (n = 17)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Generic antioxidant treatment (n = 17)
Number of subjects: 34
Study: 14662572

Group type: EXPERIMENTAL
Intervention: Hiding group (263 children, 69.6%)
Number of subjects: 378

Group type: COMPARATOR
Intervention: Nonhiding group (115 children, 30.4%)
Number of subjects: 378
Study: 10808681

Group type: EXPERIMENTAL
Intervention: Patients with essential hypertension
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with coronary heart disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypertensive men
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Men with coronary heart disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elderly men (general)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elderly women (general)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 8797615

Group type: EXPERIMENTAL
Intervention: Plasma from patients diagnosed with sepsis or septic shock
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Plasma from patients diagnosed with septic shock
Number of subjects: 32
Study: 1622948

Group type: EXPERIMENTAL
Intervention: Group A - Anterior fistula fashioned entirely in corneal tissue
Number of subjects: 78

Group type: COMPARATOR
Intervention: Group B - Fistula included cornea and sclera with trabecular meshwork and scleral spur
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 78
Study: 6383833

Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg t.i.d. after six months treatment
Number of subjects: 472

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 472
Study: 31632654

Group type: EXPERIMENTAL
Intervention: Family Nurse Partnership (FNP) programme
Number of subjects: 1618
Study: 28503930

Group type: EXPERIMENTAL
Intervention: High-fiber, low-fat diet with support (5-week education program and follow-up support through focus groups)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32
Study: 28169260

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide (setting type)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (Type VII)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate
Number of subjects: 94
Study: 24740137

Group type: EXPERIMENTAL
Intervention: Dexibuprofen 400 mg powder for oral suspension (daily dose 800 mg)
Number of subjects: 489

Group type: COMPARATOR
Intervention: Ibuprofen 400 mg powder for oral suspension (daily dose 1,600 mg)
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Dexibuprofen
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Dexibuprofen and Ibuprofen
Number of subjects: 489
Study: 22441743

Group type: EXPERIMENTAL
Intervention: Aclidinium 200 μg
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: Aclidinium 400 μg
Number of subjects: 828

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 828
Study: 19114803

Group type: EXPERIMENTAL
Intervention: Orlistat or sibutramine combined with dietary modification
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Caffeine or protein supplementation
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Diet lower in fat
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Adherence to physical activity routines
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Prolonged contact with participants
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Problem-solving therapy
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 42
Study: 18690278

Group type: EXPERIMENTAL
Intervention: Thoracic medial branch blocks with bupivacaine (Group I)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Thoracic medial branch blocks with bupivacaine and non-particulate betamethasone (Group II)
Number of subjects: 48
Study: 15942203

Group type: EXPERIMENTAL
Intervention: Acute fasting hyperglycemia
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Euglycemic hyperinsulinemia
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 10
Study: 12271721

Group type: EXPERIMENTAL
Intervention: Children's live influenza vaccine (LIVI)
Number of subjects: 2486

Group type: EXPERIMENTAL
Intervention: Adult live influenza vaccine (LIVII)
Number of subjects: 2486

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2486

Group type: EXPERIMENTAL
Intervention: Both vaccines (LIVI and LIVII)
Number of subjects: 2486
Study: 10099908

Group type: EXPERIMENTAL
Intervention: roxithromycin
Number of subjects: 202

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 202
Study: 7769082

Group type: EXPERIMENTAL
Intervention: Misoprostol (after mifepristone pre-treatment)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Misoprostol (vaginal route)
Number of subjects: 70
Study: 2186323

Group type: EXPERIMENTAL
Intervention: Combination of acylaminopenicillin plus aminoglycoside
Number of subjects: 1260

Group type: EXPERIMENTAL
Intervention: Third‐generation cephalosporin plus aminoglycoside
Number of subjects: 1260

Group type: EXPERIMENTAL
Intervention: Double beta lactam therapy
Number of subjects: 1260

Group type: EXPERIMENTAL
Intervention: Vancomycin or all three substances from phase I
Number of subjects: 1260

Group type: EXPERIMENTAL
Intervention: Amphotericin B plus 5‐flucytosine and rifampin
Number of subjects: 1260

Group type: COMPARATOR
Intervention: Continuation of the double beta lactam regimen or additional imipenem/cilastatin
Number of subjects: 1260
Study: 298350

Group type: EXPERIMENTAL
Intervention: Zimelidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zimelidine and Placebo
Number of subjects: 0
Study: 31519284

Group type: EXPERIMENTAL
Intervention: WEACURE® (500 mg of Jadwar root powder)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 28424257

Group type: EXPERIMENTAL
Intervention: Animal-source food (ASF) supplement (mean: 144 kcal, 8.9 mg Fe, 2.7 mg Zn, 1050 μg retinoic acid equivalent vitamin A, and 5.5 μg vitamin B-12)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control snack (mean: 150 kcal, 2.0 mg Fe, 0.9 mg Zn, 0 μg retinoic acid equivalent vitamin A, and 0 μg vitamin B-12)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Animal-source food (ASF) supplement
Number of subjects: 117
Study: 24809429

Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplementation (ONS) - 2 servings (460 mL) daily providing 432 kcal, 16 g protein, and 28 micronutrients for 12 weeks
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplementation (ONS)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Dietary counselling (control)
Number of subjects: 212
Study: 24229360

Group type: EXPERIMENTAL
Intervention: Azithromycin 250 mg 3 times a week
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 21349111

Group type: EXPERIMENTAL
Intervention: comb-NBUVB (NBUVB therapy with daily application of antimicrobial gel)
Number of subjects: 10

Group type: COMPARATOR
Intervention: mono-NBUVB (NBUVB therapy without antimicrobial gel)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: NBUVB treatment (both comb-NBUVB and mono-NBUVB)
Number of subjects: 10
Study: 19583608

Group type: EXPERIMENTAL
Intervention: TEG algorithm group (n = 114)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Clinician-directed transfusion group (n = 110)
Number of subjects: 224
Study: 17407593

Group type: EXPERIMENTAL
Intervention: Nicotine dependent individuals who were successful in abstaining from cigarette smoking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotine dependent individuals who were not successful in abstaining from cigarette smoking
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects free from substantial lifetime use of any addictive substance
Number of subjects: 0
Study: 15016487

Group type: EXPERIMENTAL
Intervention: rt-PA
Number of subjects: 2775

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2775
Study: 12504395

Group type: EXPERIMENTAL
Intervention: Oestradiol valerate (2 mg, daily for 2 years)
Number of subjects: 1017

Group type: COMPARATOR
Intervention: Placebo (daily for 2 years)
Number of subjects: 1017
Study: 9793663

Group type: EXPERIMENTAL
Intervention: Lumbar puncture
Number of subjects: 66

Group type: COMPARATOR
Intervention: Bone marrow aspiration
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Dural puncture
Number of subjects: 66
Study: 8558626

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (300 mg per kg of body mass)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (100 mg sodium chloride per kg of body mass and 200 mg calcium carbonate per kg of body mass)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Neither (Control)
Number of subjects: 12
Study: 2646504

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 637277

Group type: EXPERIMENTAL
Intervention: Caudad injection via a 22 gauge Whitacre needle
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cephalad or lateral injection via a 22 gauge Whitacre needle
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Low dose caudally directed injections
Number of subjects: 21
Study: 29807715

Group type: EXPERIMENTAL
Intervention: Low glycemic index carbohydrates after 55 minutes of aerobic exercise
Number of subjects: 26

Group type: COMPARATOR
Intervention: High glycemic index carbohydrates after 55 minutes of aerobic exercise
Number of subjects: 26
Study: 29264882

Group type: EXPERIMENTAL
Intervention: Removable appliance therapy with electronic sensors for cooperation assessment
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Caregivers' traits (generalized sense of efficacy, conscientiousness, severity of requirements)
Number of subjects: 38
Study: 24703014

Group type: EXPERIMENTAL
Intervention: Peer Educator Training Program
Number of subjects: 0
Study: 23501141

Group type: EXPERIMENTAL
Intervention: Internal motivations for seeking treatment
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Occupational concerns (internal motivator)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Interpersonal-family concerns (internal motivator)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: General motivations for seeking treatment
Number of subjects: 180
Study: 21808934

Group type: EXPERIMENTAL
Intervention: High-intensity functional exercise program
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Protein-enriched drink
Number of subjects: 177
Study: 19335909

Group type: EXPERIMENTAL
Intervention: Multi-factorial falls prevention program including home exercise and individualised falls prevention strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sub-study evaluating fear of falling, falls, and function over twelve months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sub-study evaluating residual impairment in gait stability and obstacle crossing
Number of subjects: 0
Study: 16404515

Group type: EXPERIMENTAL
Intervention: High-dose intracoronary brachytherapy (24 Gy)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 32
Study: 15389418

Group type: EXPERIMENTAL
Intervention: Dieting protocols (specific protocols not detailed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inclusion of a 1‐ to 2‐week run‐in period
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increasing initial randomized sample size by 10% to 25%
Number of subjects: 0
Study: 10885606

Group type: EXPERIMENTAL
Intervention: Docetaxel 100 mg/m2 every 3 weeks
Number of subjects: 43
Study: 8813873

Group type: EXPERIMENTAL
Intervention: Imipramine 25 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Mianserin 10 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 1919404

Group type: EXPERIMENTAL
Intervention: 2.6% sodium hypochlorite irrigation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tap water irrigation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ultrasonic instrumentation with either irrigant
Number of subjects: 20
Study: 6287931

Group type: EXPERIMENTAL
Intervention: Ceftriaxone in 1% lidocaine diluent
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ceftriaxone in water diluent
Number of subjects: 12
Study: 31863206

Group type: EXPERIMENTAL
Intervention: Pregabalin (PG) 150 mg per os, 2 doses preoperatively
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 30762399

Group type: EXPERIMENTAL
Intervention: Brief Behavioral Therapy for Cancer‐Related Insomnia (BBT‐CI)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Healthy-eating control intervention (HEAL)
Number of subjects: 71
Study: 28694327

Group type: EXPERIMENTAL
Intervention: Nutritional intervention based on the 2010 USDA Dietary Guidelines for Americans (DGA) for fruit and vegetable intake for 8 weeks
Number of subjects: 0
Study: 26284299

Group type: EXPERIMENTAL
Intervention: High intake of fish and mussels (1 kg/week for 26 weeks)
Number of subjects: 102

Group type: COMPARATOR
Intervention: No intervention (expected to eat less than 300 g of fish and mussels per week)
Number of subjects: 102
Study: 24781224

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 62

Group type: COMPARATOR
Intervention: Atypical neuroleptics (control group)
Number of subjects: 62
Study: 23026173

Group type: EXPERIMENTAL
Intervention: 0.125% levobupivacaine plus 3 mg fentanyl
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.1% levobupivacaine plus 3 mg fentanyl
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.05% levobupivacaine plus 3 mg fentanyl
Number of subjects: 60
Study: 19740915

Group type: EXPERIMENTAL
Intervention: CyA (AUC 1700‐2000 ng/ml) + PSL (0.8 mg/kg/day)
Number of subjects: 52

Group type: COMPARATOR
Intervention: PSL alone (1.0 mg/kg/day)
Number of subjects: 52
Study: 18801159

Group type: EXPERIMENTAL
Intervention: Standard arm: total dose 6.0 Gy in single fractions of 1.0 Gy applied twice a week
Number of subjects: 200

Group type: COMPARATOR
Intervention: Experimental arm: total dose 0.6 Gy in single fractions of 0.1 Gy applied twice a week (acting as a placebo)
Number of subjects: 200
Study: 16052085

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole prophylaxis initiation at WHO stage >= 2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed prophylaxis initiation until WHO stage >= 3
Number of subjects: 0

Group type: COMPARATOR
Intervention: CD4-based co-trimoxazole initiation (< 500, < 200, < 50 x 10(6) CD4 cells/l)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early co-trimoxazole prophylaxis
Number of subjects: 0
Study: 11791038

Group type: EXPERIMENTAL
Intervention: Pulse pressure (10 mmHg wider at baseline)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mean pressure
Number of subjects: 0
Study: 10509848

Group type: EXPERIMENTAL
Intervention: Dorzolamide hydrochloride ophthalmic solution 2% TID
Number of subjects: 194

Group type: COMPARATOR
Intervention: Pilocarpine hydrochloride 2% QID
Number of subjects: 194
Study: 8750152

Group type: EXPERIMENTAL
Intervention: IFN-alpha + coumarin + cimetidine
Number of subjects: 148

Group type: COMPARATOR
Intervention: IFN-alpha monotherapy
Number of subjects: 148
Study: 2709166

Group type: EXPERIMENTAL
Intervention: Educational and environmental strategies (three intervention groups with varying levels of potency)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Feedback about health status, persuasive information about risk reduction, and a supportive environment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control company
Number of subjects: 0
Study: 819597

Group type: EXPERIMENTAL
Intervention: Idoxuridine (given hourly by day and at 2-hr intervals by night for three days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human interferon (1.1 X 10(7) international units/ml, applied daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human interferon (given once daily for seven days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monkey interferon
Number of subjects: 0
Study: 31301442

Group type: EXPERIMENTAL
Intervention: Bone-Anchored Annular Closure Device (ACD)
Number of subjects: 550

Group type: COMPARATOR
Intervention: Discectomy alone (controls)
Number of subjects: 550
Study: 28565886

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 300,000 U orally followed by 50,000 U/month for 6 months
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 35
Study: 25970146

Group type: EXPERIMENTAL
Intervention: Organic khorasan wheat products (bread, pasta, biscuits, crackers)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Organic khorasan wheat products
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control wheat products
Number of subjects: 22
Study: 23428284

Group type: EXPERIMENTAL
Intervention: Health Belief Model factors
Number of subjects: 1450

Group type: EXPERIMENTAL
Intervention: Believing themselves at risk for cervical cancer
Number of subjects: 1450

Group type: EXPERIMENTAL
Intervention: Believing cervical cancer changes life
Number of subjects: 1450

Group type: EXPERIMENTAL
Intervention: Believing a Pap test is important for staying healthy
Number of subjects: 1450

Group type: EXPERIMENTAL
Intervention: Not understanding what is done during a Pap test
Number of subjects: 1450

Group type: EXPERIMENTAL
Intervention: Being scared to know having cervical cancer
Number of subjects: 1450

Group type: EXPERIMENTAL
Intervention: Taking a Pap test is embarrassing
Number of subjects: 1450

Group type: EXPERIMENTAL
Intervention: Not being available by doctors at convenient times
Number of subjects: 1450

Group type: EXPERIMENTAL
Intervention: Having too much time for a test
Number of subjects: 1450

Group type: EXPERIMENTAL
Intervention: Believing no need for a Pap test when feeling well
Number of subjects: 1450

Group type: EXPERIMENTAL
Intervention: Being confident in getting a test
Number of subjects: 1450
Study: 22094836

Group type: EXPERIMENTAL
Intervention: Calcitriol (0.25 μg 1,25‐dihydroxy cholecalciferol per capsule, 2 capsules per day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 70
Study: 19018813

Group type: EXPERIMENTAL
Intervention: Mohs micrographic surgery (MMS) on ear lesions at Location 1 (helix, antihelix, tragus)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Mohs micrographic surgery (MMS) on ear lesions at Location 2 (retroauricular)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Mohs micrographic surgery (MMS) on ear lesions at Location 3 (conchal bowl, scapha, triangular fossa)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control group (NMSC cases from the nose)
Number of subjects: 142
Study: 22299644

Group type: COMPARATOR
Intervention: 2000 µg BDP solution with 5 g oral charcoal (OralC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 2000 µg BDP solution without oral charcoal (Oral)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10,100 µg inhalations from Qvar(®) pMDI (Qvar)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: eight 250 µg inhalations from Clenil(®) pMDI (Clenil)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Qvar compared with Clenil
Number of subjects: 12
Study: 15511598

Group type: EXPERIMENTAL
Intervention: Non-obese BED women
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Obese BED women
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Obese non-binge eating women
Number of subjects: 182

Group type: COMPARATOR
Intervention: Non-obese healthy women
Number of subjects: 182

Group type: COMPARATOR
Intervention: Bulimic women
Number of subjects: 182
Study: 14630756

Group type: COMPARATOR
Intervention: Acetic acid ear drops
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Steroid and acetic acid ear drops
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Steroid and antibiotic ear drops
Number of subjects: 213
Study: 9797832

Group type: EXPERIMENTAL
Intervention: Ivermectin (400 micrograms/kg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) (10 mg/kg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ivermectin, DEC, and Placebo
Number of subjects: 120
Study: 7653663

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (ANF) 50 micrograms, then 50 ng.kg‐1.min‐1
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline (as vehicle)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Nitroprusside infusion (0.4 micrograms.kg‐1.min‐1)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (ANF)
Number of subjects: 7